Skip to main content

06 - References

References

Schizophrenia and related psychoses CHAPTER 1 References

  1. Zohar J, et al. Neuroscience-­based Nomenclature (NbN): a call for action. World J Biol Psychiatry 2016; 17:318–320.
  2. National Institute for Health and Care Excellence. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. Clinical guideline [CG76]. 2009 (last updated March 2019, last checked December 2024); https://www.nice.org.uk/ Guidance/CG76.
  3. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Clinical guideline [CG178]. 2014 (last checked November 2024); https://www.nice.org.uk/guidance/cg178.
  4. Lieberman JA, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209–1223.
  5. Jones PB, et al. Randomized controlled trial of the effect on quality of life of second-­ vs first-­generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63:1079–1087.
  6. Tandon R, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008; 100:20–38.
  7. Tarsy D, et al. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol 2011; 100:601–616.
  8. Zhang JP, et al. Efficacy and safety of individual second-­generation vs. first-­generation antipsychotics in first-­episode psychosis: a systematic review and meta-­analysis. Int J Neuropsychopharmacol 2013; 16:1205–1218.
  9. Zhu Y, et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-­analyses. Lancet Psychiatry; 4:694–705.
  10. Leucht S, et al. A meta-­analysis of head-­to-­head comparisons of second-­generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166:152–163.
  11. Davis JM, et al. A meta-­analysis of the efficacy of second-­generation antipsychotics. Archives of General Psychiatry 2003; 60:553–564.
  12. Leucht S, et  al. Second-­generation versus first-­generation antipsychotic drugs for schizophrenia: a meta-­analysis. Lancet 2009; 373:31–41.
  13. Leucht S, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-­treatments meta-­analysis. Lancet 2013; 382:951–962.
  14. Huhn M, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-­episode schizophrenia: a systematic review and network meta-­analysis. Lancet 2019; 394:939–951.
  15. Voruganti L, et al. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl) 2004; 171:121–132.
  16. Leucht S, et al. Long-­term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-­analysis. World Psychiatry 2023; 22:315–324.
  17. Leucht S, et al. Sixty years of placebo-­controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-­analysis, and meta-­regression of efficacy predictors. Am J Psychiatry 2017; 174:927–942.
  18. Siskind D, et al. Clozapine v. first-­ and second-­generation antipsychotics in treatment-­refractory schizophrenia: systematic review and meta-­ analysis. Br J Psychiatry 2016; 209:385–392.
  19. Samara MT, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-­resistant schizophrenia: a network meta-­analysis. JAMA Psychiatry 2016; 73:199–210.
  20. Taylor DM. Clozapine for treatment-­resistant schizophrenia: still the gold standard? CNS Drugs 2017; 31:177–180.
  21. Kane JM, et al. The role of clozapine in treatment-­resistant schizophrenia. JAMA Psychiatry 2016; 73:187–­188.
  22. Manu P, et al. Prediabetes in patients treated with antipsychotic drugs. J Clin Psychiatry 2012; 73:460–466.
  23. Rummel-­Kluge C, et al. Head-­to-­head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-­analysis. Schizophr Res 2010; 123:225–233.
  24. Sorensen HJ, et al. Schizophrenia, antipsychotics and risk of hip fracture: a population-­based analysis. Eur Neuropsychopharmacol 2013; 23:872–878.
  25. Trollor JN, et al. Comparison of neuroleptic malignant syndrome induced by first-­ and second-­generation antipsychotics. Br J Psychiatry 2012; 201:52–56.
  26. Masopust J, et  al. Risk of venous thromboembolism during treatment with antipsychotic agents. Psychiatry Clin Neurosci 2012; 66:541–552.
  27. Pope A, et al. Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used. Br J Psychiatry 2010; 197:67–72.
  28. Bailey L, et al. Estimating the optimal dose of flupentixol decanoate in the maintenance treatment of schizophrenia: a systematic review of the literature. Psychopharmacology (Berl) 2019; 236:3081–3092.
  29. Falkai P. Limitations of current therapies: why do patients switch therapies? Eur Neuropsychopharmacol 2008; 18 Suppl 3:S135–S139.
  30. Yusufi B, et al. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol 2007; 22:238–243.
  31. Day JC, et al. A comparison of patients’ and prescribers’ beliefs about neuroleptic side-­effects: prevalence, distress and causation. Acta Psychiatr Scand 1998; 97:93–97.
  32. Waddell L, et al. A new self-­rating scale for detecting atypical or second-­generation antipsychotic side effects. J Psychopharmacol 2008; 22:238–243.
  33. Ohlsen RI, et al. Interrater reliability of the Antipsychotic Non-­Neurological Side-­Effects Rating Scale measured in patients treated with clozapine. J Psychopharmacol 2008; 22:323–329.

6 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 34. Tiihonen J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-­up study. BMJ 2006; 333:224. 35. Leucht C, et al. Oral versus depot antipsychotic drugs for schizophrenia—­a critical systematic review and meta-­analysis of randomised long-­ term trials. Schizophr Res 2011; 127:83–92. 36. Leucht S, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-­analysis. Lancet 2012; 379:2063–2071. 37. Schneider-­Thoma J, et al. Comparative efficacy and tolerability of 32 oral and long-­acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-­analysis. Lancet 2022; 399:824–836. 38. Kane J, et al. Clozapine for the treatment-­resistant schizophrenic. A double-­blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789–796. 39. McEvoy JP, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163:600–610. 40. Lewis SW, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-­generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32:715–723. 41. Stone JM, et al. Review: the biological basis of antipsychotic response in schizophrenia. J Psychopharmacol 2010; 24:953–964. 42. Agid O, et al. An algorithm-­based approach to first-­episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 2011; 72:1439–1444. 43. Kahn RS, et al. Amisulpride and olanzapine followed by open-­label treatment with clozapine in first-­episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-­phase switching study. Lancet Psychiatry 2018; 5:797–807.

No comments to display

Back to top